西班牙专利ES2621220T9 Macrocyclic derivatives for the treatment of proliferative diseases

专利PDF首页>>西班牙专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:

公开号:ES2621220T9
申请号:ES13717555.0T
申请日:2013-02-20
公开日:2017-11-23
发明作者:Simon Bailey；Benjamin Joseph Burke；Michael Raymond Collins；Jingrong Jean Cui；Judith Gail Deal；Robert Louis Hoffman；Qinhua Huang；Ted William Johnson；Robert Steven Kania；John Charles Kath；Phuong Thi Quy Le；Michele Ann Mctigue；Cynthia Louise Palmer；Paul Francis Richardson；Neal William Sach
申请人:Pfizer Inc；
IPC主号:

专利说明:

image 1
image2
image3
image4
image5
5
10
fifteen
twenty
25
30
35

embodiments, one of R3 and R4 is hydrogen and the other is methyl.
In another embodiment of this aspect, A is a ring selected from the group consisting of phenyl, pyridine, pyrimidine, pyridazine, pyrazine, triazine, pyrazole, imidazole, triazole, tetrazol, thiazole, isothiazole, oxazole and isoxazole. In specific embodiments of this aspect, A is a ring selected from the group consisting of the specific rings indicated as suitable for compounds of the formula ɸ, above.
In another embodiment of this aspect, A is a ring selected from phenyl, pyridine, triazine, pyrazole, imidazole, thiazole, isothiazole, oxazole and isoxazole. In some of such embodiments, each of R3 and R4 is independently selected from the group consisting of hydrogen and C1-C6 alkyl.
In another embodiment of this aspect, A is a ring selected from the group consisting of phenyl, pyridine, pyrimidine, pyridazine, pyrazine, triazine, pyrazole, imidazole, triazole, tetrazol, thiazole, isothiazole, oxazole and isoxazole. In some of such embodiments, each of R3 and R4 is independently selected from the group consisting of hydrogen and C1-C6 alkyl.
In another embodiment of this aspect, A is a ring selected from the group consisting of phenyl, pyridine, pyrimidine, pyridazine, pyrazine, triazine, pyrazole, imidazole, triazole, tetrazol, thiazole, isothiazole, oxazole and isoxazole; each R2 is independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, -S (O) tR7, S (O) 2NR7R8, -OR7, -O (CR5R6) (CR5R6) qOR7, -O ( CR5R6) (CR5R6) qR7 and -CN; and each of R3 and R4 is independently selected from the group consisting of hydrogen and C1-C6 alkyl.
In another aspect, the invention provides a compound of the formula (VI)
image6
in which:
A is a ring selected from C6-C12 aryl and 5-6 membered heteroaryl; R1 is selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic and 5-6 membered heteroaryl, wherein each hydrogen in said C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic and 5-6 membered heteroaryl optionally may be optionally substituted Halogen independent, -OH, -NH-2, -S (O) tR9, -S (O) 2NR9R10, -S (O) 2OR9, -NO2, -CN, -OR9, -C (O) R9, - OC (O) R9, -NR9C (O) R10, C (O) OR9, -C (= NR9) NR9R10, -NR9C (O) NR9R10, -NR9S (O) 2R10 or -C (O) NR9R10; each R2 is independently selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic, 5-6 heteroaryl members, -S (O) tR7, -S (O) 2NR7R8, -S (O) 2OR7, -NO2, - (CR5R6) qNR7R8, -N (CR5R6) (CR5R6) qNR7R8rOR7, O (CR5R6) (CR5R6) qOR7 , -O (CR5R6) (CR5R6) qR7, -CN, -C (O) R7, -OC (O) R7, -O (CR5R6) qR7, -N R7C (O) R8, (CR5R6) qC (O) OR7, - (CR5R6) qNR7R8, -C (= NR7) NR7R8, -NR7C (O) NR7R8, -NR7S (O) 2R8 and - (CR5R6) qC (O) NR7R8; wherein each hydrogen in said C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C12 aryl, 3-12 membered heteroalicyclic and 5-6 membered heteroaryl optionally may be optionally substituted Halogen independent, -OH, -NH-2, -S (O) tR9, -S (O) 2NR9R10, -S (O) 2OR9, -NO2, -OR9, -CN, -C (O) R9, - OC (O) R9, -NR9C (O) R10, -C (O) OR9, -C (= NR9) NR9R10, -NR9C (O) NR9R10, -N R9S (O) 2R10 or -C (O) NR9R10; each of R3 and R4 is independently selected from hydrogen, C1-C6 alkyl and C3-C6 cycloalkyl, wherein each hydrogen in C1-C6 alkyl and C3-C6 cycloalkyl may optionally be independently substituted with halogen, -OH, -NH-2, -S (O) tR9, -S (O) 2NR9R10, -S (O) 2OR9, -NO2, -CN, -OR9, -C (O) R9,
7
image7
image8
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55

or a pharmaceutically acceptable salt thereof.
In another aspect, the invention provides a pharmaceutical composition comprising a compound of the formula (I) described herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises two or more pharmaceutically acceptable carriers and / or excipients.
In another aspect, the invention provides a compound of formula (I) described herein, or a pharmaceutically acceptable salt thereof, for use as a medicament. In one embodiment, the medicament is for use in the treatment of abnormal cell growth in a mammal. In frequent embodiments, abnormal cell growth is cancer. In one embodiment, the medicament is for use in the treatment of abnormal ALK-mediated cell growth in a mammal. In another embodiment, the medicament is for use in the treatment of abnormal cell growth mediated by an EML4-ALK fusion protein in a mammal. In some of such embodiments, the EML4-ALK fusion protein has at least one mutation. In one embodiment, the mutation is L1196M. In another embodiment, the mutation is C1156Y.
In one embodiment, the invention provides a compound of formula (I) described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of abnormal cell growth in a mammal. In frequent embodiments, abnormal cell growth is cancer. In one embodiment, the abnormal cell growth is mediated by ALK. In another embodiment, the abnormal cell growth is mediated by an EML4-ALK fusion protein. In some of such embodiments, the EML4-ALK fusion protein has at least one mutation. In one embodiment, the mutation is L1196M. In another embodiment, the mutation is C1156Y.
The disclosure also provides therapeutic methods and their uses, comprising administering a compound of the invention, or a pharmaceutically acceptable salt thereof, alone or in combination with another therapeutic or palliative agent, to a mammal in need of such treatment. In a preferred embodiment, the mammal is a human being. In other embodiments, the mammal is a dog or a cat.
In one aspect, the disclosure provides a method for the treatment of abnormal cell growth in a mammal, which comprises administering to a mammal a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
In another aspect, the disclosure provides a method for the treatment of abnormal cell growth in a mammal, which comprises administering to a mammal an amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, in combination with an amount of a antitumor agent, whose amounts are effective together in the treatment of said abnormal cell growth. In some embodiments, the antitumor agent is selected from the group consisting of mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers , antibodies, cytotoxic, antihormones and antiandrogens.
In one embodiment, the disclosure provides a method for the treatment of abnormal cell growth in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of formula (I) described herein, or a pharmaceutically acceptable salt of the same. In frequent embodiments, abnormal cell growth is cancer. In one embodiment, the abnormal cell growth is mediated by ALK. In another embodiment, the abnormal cell growth is mediated by an EML4-ALK fusion protein. In some of such embodiments, the EML4-ALK fusion protein has at least one mutation. In one embodiment, the mutation is L1196M. In another embodiment, the mutation is C1156Y.
In another aspect, the disclosure provides a method for the treatment of an ALK-mediated disorder in a mammal, which comprises administering to the mammal a compound of the invention, or a pharmaceutically acceptable salt thereof, in an amount that is effective for treatment. of said disorder.
The compounds and salts of the present invention inhibit wild-type ALK and / or certain mutant forms of ALK, including EML4-ALK fusion proteins, which include EML4-ALK fusion proteins that have at least one mutation. In one embodiment, the mutation is L1196M. In one embodiment, the mutation is C1156Y.
In one embodiment, the disclosure provides a method for the treatment of abnormal cell proliferation in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof. In some of such embodiments, abnormal cell proliferation is cancer. In one embodiment, the cancer is mediated by ALK. In another embodiment, the cancer is mediated by an EML4-ALK fusion protein. In such additional embodiments, the EML4-ALK fusion protein has at least one mutation. In one such embodiment, the mutation is L1196M. In another such embodiment, the mutation is C1156Y.
In another aspect, the invention provides a compound of formula (I) described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of abnormal cell growth in a mammal. In a further aspect, the invention provides the use of a compound of formula (I) described in the
10
image9
image10
image11
5
10
fifteen
twenty
25
30
35
40

carbon atoms ("C1-C6 alkoxy"), or 1 to 4 carbon atoms ("C1-C4 alkoxy"). For example, C1-C4 alkoxy includes -OCH3, -OCH2CH3, -OCH (CH3) 2, -OC (CH3) 3, and the like. Such groups may be referred to herein as methoxy, ethoxy, isopropoxy, tert-butyloxy, etc. Alkoxy groups may be unsubstituted or substituted in the alkyl portion with the same groups as described herein as suitable for alkyl. In particular, the alkoxy groups may be substituted with one or more halo groups, up to the total number of hydrogen atoms present in the alkyl portion. Therefore, C1-C4 alkoxy includes halogenated alkoxy groups, for example, trifluoromethoxy and 2,2-difluoroethoxy (ie -OCF3 and -OCH2CHF2).
Similarly, "thioalkoxy" refers to a monovalent -S-alkyl group, in which the alkyl portion has the specified number of carbon atoms, and may be optionally substituted in the alkyl portion with the same groups as described. herein as suitable for alkyl. For example, a C1-C4 thioalkoxy includes -SCH3 and -SCH2CH3.
"Halogen" or "halo" refers to fluorine, chlorine, bromine and iodine (F, Cl, Br, I). Preferably, halo refers to fluorine or chlorine (F or Cl).
"Heteroaryl" or "heteroaromatic" refers to monocyclic, fused bicyclic or polycyclic ring systems, which have well-known aromaticity characteristics and contain the specified number of atoms in the ring and include at least one heteroatom selected from N, O and S as a ring member in an aromatic ring. The inclusion of a heteroatom allows aromaticity in 5-member rings, as well as in 6-member rings. Typically, heteroaryl groups contain 5 to 20 ring atoms ("5-20 membered heteroaryl"), preferably 5 to 14 ring atoms ("5-14 membered heteroaryl"), and more preferably 5 to 12 ring atoms ("5-12 membered heteroaryl") or 5 to 6 ring atoms ("5-6 membered heteroaryl"). The heteroaryl rings are attached to the base molecule through a ring atom of the heteroaromatic ring, so that aromaticity is maintained. Therefore, the 6-membered heteroaryl rings can be attached to the base molecule through a C-ring atom, while the 5-membered heteroaryl rings can be attached to the base molecule through a C-atom or N of the ring. The heteroaryl group may be unsubstituted or substituted as further described herein. As used herein, "5-6 membered heteroaryl" refers to a monocyclic group of 5 or 6 ring atoms containing one, two or three ring heteroatoms selected from N, O, and S, where the remaining atoms of the ring are C, and also has a fully conjugated pi electron system. Substituents on adjacent atoms of the 5 or 6 membered heteroaryl ring may be combined to form a 5 or 6 membered fused carbocyclic ring optionally substituted with one or more substituents, such as oxo, C1-C6 alkyl, hydroxyl, amino and halogen , or a fused 5 or 6 membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, O and S (O) p (where p is 0, 1 or 2) optionally substituted with one or more substituents , such as oxo, C1-C6 alkyl, hydroxyl, amino and halogen. A pharmaceutically acceptable heteroaryl is one that is stable enough to bind a compound of the invention, be formulated in a pharmaceutical composition and subsequently administered to a patient in need.
Examples of 5-membered heteroaryl rings containing 1, 2 or 3 heteroatoms independently selected from O, N and S include pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, oxadiazolyl and thiadiazolyl . Preferred 6-membered heteroaryl rings contain 1 or 2 nitrogen atoms. Examples of 6-membered heteroaryl are pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl. Examples of condensed heteroaryl rings include benzofuran, benzothiophene, indole, benzoimidazole, indazole, quinoline, isoquinoline, purine, triazine, naphthyridine and carbazole.
Examples of typical monocyclic heteroaryl groups include, but are not limited to:
14

image12
Examples of 6-membered heteroaryl heteroaryl groups having adjacent atoms in the ring that form a condensed heterocyclic ring or a carbocyclic ring include, but are not limited to.
fifteen
image13

image14
The terms "heteroalicyclic", "heterocyclyl" or "heterocyclic" may be used interchangeably herein to refer to a saturated or partially unsaturated, non-aromatic ring system containing the specified number of atoms in the ring, including at least one heteroatom selected from N, O and S as a ring member, in which the heterocyclic ring is connected to the base molecule through a ring atom, which may be C or N. The heteroalicyclic rings may be fused to one or more than other heteroalicyclic or carbocyclic rings, whose condensed rings may be saturated or partially unsaturated or aromatic. Preferably, the heteroalicyclic rings contain 1 to 4 heteroatoms selected from N, O, and S as ring members, and more preferably 1 to 2 heteroatoms in the ring, with the proviso that said heteroalicyclic rings do not contain two atoms of contiguous oxygen Heteroalicyclic groups may be unsubstituted or substituted with the same groups described herein as suitable for alkyl, aryl or heteroaryl. In addition, the N atoms of the ring may optionally be
17

substituted with groups suitable for an amine, for example, alkyl, acyl, carbamoyl, sulfonyl substituents,
etc., and the ring S atoms may be optionally substituted with one or two oxo groups (i.e., S (O) p,
where p is 0, 1 or 2). Preferred heteroalicyclic groups include 3-12 heteroalicyclic groups of
in accordance with the definition of this report. As used herein, "3-12 heteroalicyclic
5 members "refers to a monocyclic or bicyclic group having 3 to 12 ring atoms, in which one, two,
three or four atoms in the ring are heteroatoms selected from N, O and S (O) p (where p is 0, 1,2) and the
Remaining atoms of the ring are C. The ring can also have one or more double bonds. However, the ring does not
It has a fully conjugated pi electron system. Substituents on two ring carbon atoms
they can be combined to form a 5 or 6 membered bridged ring that is carbocyclic or heteroalicyclic and that contains one, two or three ring heteroatoms selected from N, O and S (O) p (where p is 0, 1 or 2 ). The group
Heteroalicyclic is optionally substituted with oxo, hydroxyl, amino, C1-C6 alkyl and the like.
Examples of suitable partially unsaturated heteroalicyclic groups include, but are not limited to:
image15
Examples of suitable saturated heteroalicyclic groups include, but are not limited to:
image16
18
image17
image18
image19
image20
image21
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55

starting from a solution of the free base in an organic solvent by adding an appropriate mineral or organic acid to the solution.
Acids that can be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of which they form non-toxic acid addition salts, that is, salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, iodhydrate salts , nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, sucrate, formate, benzoate , glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p toluenesulfonate and pamoate [ie 1,1'methylene-bis- (2-hydroxy-3-naphthoate)].
Examples of salts include, but are not limited to, salts of acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate and methoxybenzoate), bicarbonate, bisulfate, bisulfite, bitartrate, borate, bromide, butine-1,4- dioate, calcium edetate, camsilate, carbonate, chloride, caproate, caprilatolato, clavulanate, citrate, decanoate, dichlorohydrate, dihydrogen phosphate, edetate, edisilate, stolate, esylate, ethyl succinate, formate, fumarate, gluceptate, gluconate, glutamate, glutamate glycolylarsanlate, heptanoate, hexin-1,6-dioate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, γ-hydroxybutyrate, iodide, isobutyrate, isothionate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, mesylate, metaphosphate sulphonate, methylsulfate, monohydrogen phosphate, mucate, napsilate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phenylacetates, Phenyl Butyrate, Phenylpropionate, Phthalate, Phosphate / Diphosphate, Polygalacturonate, Propanesulfonate, Propionate, Propriolate, Pyrophosphate, Pyrosulfate, Salicylate, Stearate, Subacetate, Subarate, Succinate, Sulfate, Sulphonate, Sulphite, Tanate, Tartrate, Tetolate, Tetolate, Tetolate, Tetolate .
Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary and tertiary amines and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts obtained from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
Compounds of the invention that include a basic moiety, such as an amino group, can form pharmaceutically acceptable salts with various amino acids, in addition to the aforementioned acids.
Compounds of the invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and particularly sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases that are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those that form non-toxic basic salts with the acidic compounds of the present invention. These salts may be prepared by any suitable procedure, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or an alkaline earth metal hydroxide or the like. These salts can also be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they can also be prepared by mixing together lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide, and then evaporating the resulting solution to dryness in the same manner as before. In any case, stoichiometric amounts of reagents are preferably used to ensure the completeness of the reaction and the maximum yields of the desired final product.
The chemical bases that can be used as reagents to prepare pharmaceutically acceptable base salts of the compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to, those obtained from such pharmacologically acceptable cations, such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium ), ammonium or water soluble amine addition salts, such as N-methylglucamine- (meglumine), and lower alkanoammonium and other pharmaceutically acceptable salts of organic amines.
Hemisalts of acids and bases may also be formed, for example, hemisulfate salts and hemicalcium salts.
For a review on suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
The salts of the present invention can be prepared according to procedures known to those skilled in the art. A pharmaceutically acceptable salt of the compounds of the invention can be easily prepared by mixing together solutions of the desired compound and acid or base, as appropriate. The salt can be precipitated from the solution and collected by filtration or can be recovered by evaporation of the solvent. The degree of ionization in the salt can vary from completely ionized to almost non-ionized.
Those skilled in the art will understand that the compounds of the invention in the form of a free base having a basic functionality can be converted into acid addition salts by treating with a stoichiometric excess of the
24
image22
image23
image24
image25
image26
image27
image28
image29
image30
image31
image32
image33
image34
image35
image36
image37
image38
image39
image40
image41
image42
image43
image44
image45
image46
image47
image48
image49
image50
image51
image52
image53
image54
image55
image56
image57
image58
image59
image60
image61
image62
image63
image64
image65
image66
image67
image68
image69
image70
image71
image72
image73
image74
image75
image76
image77
image78
image79
image80
image81
image82
image83
image84
image85
image86
image87
image88
image89
image90
image91
image92
image93
image94
image95
image96
image97
image98
image99
image100
image101
image102
image103
image104
image105
image106
image107
image108
image109
image110
image111
image112
image113
image114
image115
image116
image117
image118
image119
image120
image121
image122
image123
image124
image125
image126
image127
image128
image129
image130
image131
image132
image133
image134
image135
image136
image137
image138
image139
image140
image141
image142
image143
image144
image145
image146
image147
image148
image149
image150
image151
image152
image153
image154
image155
image156
image157
image158
image159
image160
image161
image162
image163
image164
image165
image166
image167
image168
image169
image170
image171
image172
image173
image174
image175
image176
image177
image178
image179
image180
image181
image182
image183
image184
image185
image186
image187
image188
image189
image190
image191
image192
image193
image194
image195
image196
image197
image198
image199
image200
image201
image202
image203
image204
image205
image206
image207
image208
image209
image210
image211
image212
image213
image214
image215
image216
image217
image218
image219
image220
image221
image222
image223
image224
image225
image226
image227
image228
image229
image230
image231
image232
image233
image234
image235
image236
image237
image238
image239
image240
image241
image242
image243
image244
image245
image246
image247
image248
image249
image250
image251
image252
image253
image254
image255
image256
image257
(continuation)
Example ALK TS enzyme assay (Ki)ALK L1196M enzyme assay (Ki)ELISA test for EML4-ALK TS (IC50)ELISA test for EML4-ALK L1196M (IC50)
2 <0.200 nM0.78 nM1.33 nM20.7 nM
3 <0.200 nM0.20 nM0.99 nM22.2 nM
4 <0.200 nM1.20 nM28.1 nM184 nM
0.340 nM 3.40 nM12.1 nM156 nM
6 <0.200 nM1.93 nM6.41 nM97.1 nM
7 NE14.0 nM155 nM2.68 μM
8 0.90 nM10.0 nM12.1 nM0.68 μM
9 0.20 nM1.06 nM0.35 nM9.29 nM
13.0 nM 34.0 nM
eleven <0.200 nM1.10 nM1.21 nM27.7 nM
12 10.0 nM29.0 nM34.9 nM0.70 μM
13 <0.200 nM0.29 nM0.70 nM13.9 nM
14 17.0 nM61.2 nM
<0.200 nM 2.50 nM
16 213 nM> 2.27 μM
17 <0.200 nM<0,100 nM0.30 nM4.25 nM
18 5.20 nM24.0 nM
19 <0.200 nM0.90 nM4.89 nM110 nM
34.0 nM 450 nM
twenty-one <0.200 nM<0,100 nM0.18 nM2.13 nM
22 12.0 nM17.0 nM192 nM305 nM
2. 3 <0.200 nM0.29 nM0.77 nM10.1 nM
24 4.60 nM14.0 nM
<0.200 nM 0.56 nM1.35 nM21.9 nM
26 3.30 nM15.0 nM50.5 nM0.511 μM
27 0.380 nM5.30 nM9.15 nM157 nM
28 <0.200 nM0.11 nM<0.205 nM1.40 nM
29 19.0 nM31.0 nM
<0.200 nM 0.67 nM2.64 nM67.2 nM
31 5.96 nM15.8 nM53.2 nM0.66 μM
32 <0.200 nM<0,100 nM0.841 nM5.36 nM
33 1.01 μM> 2.68 μM
3. 4 0.56 nM15.0 nM36.1 nM0.89 μM
<0.261 nM 1.10 nM0.98 nM14.3 nM
36 <0.200 nM0.560 nM0.18 nM2.64 nM
37 3.80 nM29.0 nM86.0 nM0.654 μM
38 0.610 nM5.70 nM12.0 nM201 nM
39 0.220 nM<0,100 nM14.9 nM112 nM
0.360 nM 1.60 nM21.8 nM101 nM
41 1.50 nM19.0 nM33.1 nM0.68 μM
42 500 nM2.89 nM
43 5.23 nM35.6 nM0.52 μM3.66 μM
261
(continuation)
Example ALK TS enzyme assay (Ki)ALK L1196M enzyme assay (Ki)ELISA test for EML4-ALK TS (IC50)ELISA test for EML4-ALK L1196M (IC50)
44 12.0 nM70.0 nM
Four. Five > 3.0 μM500 nM
46 0.15 nM1.10 nM10.42 nM44.70 nM
47 0.29 nM3.60 nM16.41 nM208.0 nM
48 0.2 nM1.20 nM6.75 nM68.9 nM
49 0.17 nM1.50 nM4.08 nM80.8 nM
fifty 0.14 nM1.2 nM2.37 nM29.7 nM
51 0.13 nM0.28 nM0.95 nM6.25 nM
52 1.20 nM10.2 nM4.78 nM296.4 nM
53 25.8 nM164.0 nM
54 <0.07 nM0.06 nM0.332 nM3.03 nM
55 <0.07 nM0.24 nM1.03 nM13.38 nM
56 0.2 nM0.88 nM1.83 nM35.03 nM
57 0.14 nM2.0 nM6.79 nM0.365 μM
58 <0.1 nM<0.1 nM0.33 nM2.06 nM
59 14.4 nM12.98 nM155.93 nM
60 4.6 nM21.5 nM
61 0.15 nM0.17 nM4.82 nM17.07 nM
62 137 nM253.0 nM7.605 μM> 10 μM
63 0.12 nM0.13 nM1.95 nM8.70 nM
64 34.4 nM33.3 nM0.407 μM1.19 μM
65 0.88 nM9.8 nM9.36 nM0.313 μM
66 19.3 nM122.0 nM
67 411 nM> 1.5 μM
68 207 nM> 1.5 μM
69 > 3.0 μM> 3.0 μM
70 <0.16 nM0.96 nM6.52 nM78.54 nM
71 <0.249 nM3.73 nM10.16 nM169.09 nM
72 5.1 nM28.0 nM0.347 μM4,266 μM
73 0.33 nM2.4 nM12.75 nM0.169 μM
74 0.30 nM0.86 nM11.41 nM51.93 nM
75 0.065 nM0.095 nM0.902 nM7.06 nM
76 3.1 n M1.9 nM95.65 nM108.89 nM
77 75.0 nM45.8 nM3.39 μM3.32 μM
78 2.93 nM9.61 nM40.83 nM0.350 μM
79 1.18 nM2.9 nM42.79 nM179.84 nM
80 > 3.0 μM> 3.0 μM
81 <1.88 nM3.9 nM2.25 nM51.98 nM
82 <0.2 nM2.39 nM11.15 nM182.59 nM
83 47.6 nM74 nM
84 29.3 nM90.2 nM
85 0.070 nM0.13 nM0.55 nM6.72 nM
86 <0.2 nM0.10 nM0.45 nM2.57 nM
262
(continuation)
Example ALK TS enzyme assay (Ki)ALK L1196M enzyme assay (Ki)ELISA test for EML4-ALK TS (IC50)ELISA test for EML4-ALK L1196M (IC50)
87 270.0 nM51.0 nM
88 0.2 nM0.39 nM15.51 nM190.94 nM
89 0.339 nM0.275 nM6.43 nM56.05 nM
90 0.079 nM0.249 nM1.32 nM13.00 nM
91 0.177 nM0.315 nM0.68 nM5.88 nM
92 0.23 nM0.21 nM0.47 nM3.66 nM
93 0.048 nM0.3 nM3.23 nM31.67 nM
94 0.93 μM0.688 μM
95 0.35 nM1.9 nM10.37 nM169.25 nM
97 3.50 nM24.7 nM
98 0.115 nM0.404 nM2.21 nM32.28 nM
99 3.2 nM11.7 nM52.38 nM0.531 μM
100 3.1 nM24.2 nM146.29 nM1.48 μM
101 0.12 nM0.41 nM0.92 nM8.77 nM
102 0.33 nM1.41 nM11.62 nM83.82 nM
103 9.1 nM131.0 nM
104 8.4 nM57.5 nM
105 3.0 nM16.7 nM115.04 nM0.642 μM
106 > 3 μM> 3 μM
107 88.5 nM179.0 nM
108 <0.06 nM<0.05 nM0.068 nM0.50 nM
109 8.1 nM4.7 nM11,029 nM55.56 nM
110 0.56 nM7.3 nM9.99 nM0.447 μM
111 0.059 nM0.54 nM1.42 nM32.49 nM
112 0.32 nM3.4 nM9.67 nM247.76 nM
113 0.20 nM0.46 nM0.68 nM9.56 nM
114 0.271 nM1.36 nM3.29 nM78.24 nM
115 <0.08 nM0.09 nM0.96 nM8.18 nM
116 > 1.5 μM> 3 μM> 10 μM> 10 μM
117 2.18 nM17.8 nM35.22 nM393.0 nM
118 17.8 nM64.7 nM217.23 nM1.402 μM
119 1.6 nM13.4 nM7.79 nM264.0 nM
120 146.0 nM0.821 μM2.11 μM> 10 μM
121 132.0 nM273.0 nM
122 0.27 nM0.70 nM9.27 nM52.31 nM
123 205.0 nM333.0 nM4.79 μM> 10 μM
124 2.10 nM7.4 nM56.17 nM0.873 μM
125 0.11 nM0.49 nM2.30 nM49.08 nM
126 0.54 μM1.07 μM
127 0.099 nM0.52 nM2.50 nM64.97 nM
128 138.0 nM386.0 nM
129 353.0 nM> 1.5 μM
130 > 3 μM> 3 μM
263

权利要求:
Claims (1)
[1]
image 1
image2
image3
image4

类似技术:

公开号 | 公开日 | 专利标题

ES2621220T9|2017-11-23|Macrocyclic derivatives for the treatment of proliferative diseases

CN105481789B|2020-05-19|Indoleamine-2,3-dioxygenase inhibitor and preparation method thereof

ES2660210T3|2018-03-21|Indolcarboxamide derivatives and uses thereof

ES2565019T3|2016-03-30|New pharmaceutical compounds

ES2797252T3|2020-12-01|Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

ES2729243T3|2019-10-31|Compounds and compositions as kinase inhibitors

WO2013066838A1|2013-05-10|Compounds and methods

BR122019019582B1|2021-07-13|THIENO[3,2-D]PYRIMIDINE DERIVED COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THE SAID COMPOUNDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF A DISEASE CAUSED BY ABNORMAL ACTIVATION OF A PROTEIN KINASE

PT93823B|1996-09-30|PROCESS FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

ES2663237T3|2018-04-11|Prodrugs of the amino kinase kinase inhibitor

BRPI0618752A2|2011-09-27|bicyclically substituted pyrimidone derivatives

ES2618891T3|2017-06-22|N, N'-diariltioureas and N, N¿-cyclic N-diarylureas as androgen receptor antagonists, anticancer agent, method of producing and using it

AU2015335783B2|2019-10-03|Tricyclic atropisomer compounds

JPWO2008114857A1|2010-07-08|Process for producing aminoacetylpyrrolidinecarbonitrile derivative

ES2620119T3|2017-06-27|Novel heterocyclic derivatives as modulators of kinase activity

TW200906825A|2009-02-16|Inhibitors of protein kinases

ES2821102T3|2021-04-23|Azaquinazolinecarboxamide derivatives

WO2018118842A1|2018-06-28|Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof

BR112019021703A2|2020-05-12|HETEROAROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION AS VANINE INHIBITORS

US20190016670A1|2019-01-17|Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

TW200804285A|2008-01-16|New pyridin-3-amine derivatives

JP2022515787A|2022-02-22|A novel hydrazone derivative in which an aryl or heteroaryl group is substituted with a terminal amine group and its use.

AU2018361249A1|2020-06-11|Aminoimidazopyridazines as kinase inhibitors

AU2019218187B2|2021-10-14|Dioxinoquinoline compounds, preparation method and uses thereof

ES2769279T3|2020-06-25|Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same

同族专利:

公开号 | 公开日

LUC00131I1|2019-10-11|

MD4590C1|2019-03-31|

EA026155B9|2017-06-30|

NO2019034I1|2019-08-19|

JP6002825B2|2016-10-05|

EA026155B1|2017-03-31|

CN104169286B|2016-06-08|

NL301006I2|2020-04-14|

HUS1900040I1|2019-09-30|

US9133215B2|2015-09-15|

PH12014501992B1|2014-11-24|

TWI476199B|2015-03-11|

CA2863892C|2016-08-30|

PL2822953T3|2017-07-31|

RS55814B1|2017-08-31|

CA2863892A1|2013-09-12|

WO2013132376A1|2013-09-12|

ME02630B|2017-06-20|

EP2822953B9|2017-06-21|

BR112014022106A2|2017-07-11|

JP2016041709A|2016-03-31|

LTC2822953I2|2020-12-28|

KR20140137414A|2014-12-02|

CN104169286A|2014-11-26|

CY1118771T1|2017-07-12|

AP2014007881A0|2014-08-31|

DK2822953T5|2017-09-11|

PT2822953T|2017-04-06|

AU2013229173B2|2017-06-01|

HUE034118T2|2018-01-29|

LTPA2019519I1|2019-11-11|

ZA201406244B|2015-05-27|

AU2013229173A1|2014-08-21|

US20130252961A1|2013-09-26|

GEP201606560B|2016-10-25|

JP5823066B2|2015-11-25|

GT201400187A|2015-10-15|

EP2822953A1|2015-01-14|

HK1199247A1|2015-06-26|

EP2822953B1|2017-02-01|

US8680111B2|2014-03-25|

IL234062A|2017-08-31|

CO7061081A2|2014-09-19|

DOP2014000188A|2014-11-16|

US20140135339A1|2014-05-15|

LUC00131I2|2020-07-16|

JP2015510879A|2015-04-13|

PE20142339A1|2015-01-15|

ES2621220T3|2017-07-03|

EA201491394A1|2015-05-29|

MX350844B|2017-09-22|

DK2822953T3|2017-04-03|

PH12014501992A1|2014-11-24|

HRP20170287T1|2017-04-21|

LT2822953T|2017-04-10|

KR101692600B1|2017-01-03|

UY34657A|2013-10-31|

MD20140086A2|2015-01-31|

NI201400102A|2015-03-05|

SG11201404451TA|2014-09-26|

SI2822953T1|2017-04-26|

CR20140370A|2014-08-21|

HRP20170287T2|2017-11-03|

NZ627900A|2016-08-26|

MD4590B1|2018-08-31|

AR090230A1|2014-10-29|

CL2014002084A1|2014-11-03|

TW201350484A|2013-12-16|

MX2014010716A|2014-09-22|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

KR0166088B1|1990-01-23|1999-01-15|.|Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof|

US5376645A|1990-01-23|1994-12-27|University Of Kansas|Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof|

GB9518953D0|1995-09-15|1995-11-15|Pfizer Ltd|Pharmaceutical formulations|

WO2000035296A1|1996-11-27|2000-06-22|Wm. Wrigley Jr. Company|Improved release of medicament active agents from a chewing gum coating|

GB9711643D0|1997-06-05|1997-07-30|Janssen Pharmaceutica Nv|Glass thermoplastic systems|

DE10239042A1|2002-08-21|2004-03-04|Schering Ag|New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections|

WO2004078682A2|2003-03-05|2004-09-16|Irm Llc|Cyclic compounds and compositions as protein kinase inhibitors|

PA8603801A1|2003-05-27|2004-12-16|Janssen Pharmaceutica Nv|DERIVATIVES OF QUINAZOLINE|

WO2006000020A1|2004-06-29|2006-01-05|European Nickel Plc|Improved leaching of base metals|

MX2007002310A|2004-08-26|2007-05-08|Pfizer|Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors.|

AU2005276135B2|2004-08-26|2011-04-28|Pfizer Inc.|Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors|

EP1710246A1|2005-04-08|2006-10-11|Schering Aktiengesellschaft|Sulfoximine-pyrimidine Macrocycles and the salts thereof,a process for making them, and their pharmaceutical use against cancer|

PT1959955E|2005-12-05|2011-01-04|Pfizer Prod Inc|Method of treating abnormal cell growth|

CA2632283C|2005-12-05|2011-06-21|Pfizer Products Inc.|Polymorphs of a c-met/hgfr inhibitor|

EP2120578B1|2007-01-19|2014-11-19|Xcovery, INC.|Kinase inhibitor compounds|

CA2679126A1|2007-03-01|2008-09-04|Chugai Seiyaku Kabushiki Kaisha|Macrocyclic compound|

KR20090110381A|2007-03-13|2009-10-21|화이자 프로덕츠 인크.|Erythromycin-based macrolides|

JP2011511005A|2008-02-04|2011-04-07|オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド|2-aminopyridine kinase inhibitor|

US8871753B2|2008-04-24|2014-10-28|Incyte Corporation|Macrocyclic compounds and their use as kinase inhibitors|

US8580777B2|2008-06-06|2013-11-12|Sanofi|Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa|

KR20110073500A|2008-09-08|2011-06-29|메르크 파텐트 게엠베하|Macrocyclics pyrimidines as aurora kinase inhibitors|

US8765727B2|2009-01-23|2014-07-01|Incyte Corporation|Macrocyclic compounds and their use as kinase inhibitors|

JP2013508323A|2009-10-21|2013-03-07|シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ|Synthetic macrocyclic amide HDAC6 inhibitor compounds and their use as therapeutic agents|

US8383793B2|2010-04-15|2013-02-26|St. Jude Children's Research Hospital|Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase kinase inhibitors|

WO2011138751A2|2010-05-04|2011-11-10|Pfizer Inc.|Heterocyclic derivatives as alk inhibitors|

CR20170098A|2010-05-20|2017-07-17|Array Biopharma Inc|MACROCICLICAL COMPOUNDS AS QUINASA TRK INHIBITORS|

US8975232B2|2010-07-29|2015-03-10|President And Fellows Of Harvard College|Macrocyclic kinase inhibitors and uses thereof|

WO2012125603A1|2011-03-16|2012-09-20|Cephalon, Inc.|Macrocyclic compounds as alk, fak and jak2 inhibitors|EP3865475A1|2013-01-31|2021-08-18|Vertex Pharmaceuticals Incorporated|Process for preparing pyridone amides which are modulators of sodium channels and intermediate compounds used therein|

ES2656189T3|2013-06-28|2018-02-26|Pfizer Inc.|Solid forms of a macrocyclic kinase inhibitor|

CN104513253A|2013-10-01|2015-04-15|南京波尔泰药业科技有限公司|Macrocyclic compounds for the treatment of proliferative diseases|

RU2692766C1|2013-12-13|2019-06-27|Вертекс Фармасьютикалз Инкорпорейтед|Prodrugs of pyridonamides used as modulators of sodium channels|

US10231965B2|2014-02-20|2019-03-19|Ignyta, Inc.|Molecules for administration to ROS1 mutant cancer cells|

CN103772272A|2014-03-04|2014-05-07|定陶县友帮化工有限公司|Synthetic method of 2-BOC-amido-3-hydroxy-5-bromopyridine|

CN107207528B|2014-08-20|2019-06-21|苏州韬略生物科技有限公司|Big ring and its application method are substituted as kinase inhibitor|

WO2016026423A1|2014-08-20|2016-02-25|Teligene Ltd|Substituted macrocycles useful as kinases inhibitors and methods of use thereof|

MX2017004515A|2014-10-13|2017-10-31|Atrin Pharmaceuticals LLC|Ataxia telengiectasia and rad3-relatedprotein kinase inhibitors.|

EP3227276B1|2014-12-02|2021-09-01|Ignyta, Inc.|Combinations for the treatment of neuroblastoma|

US10316044B2|2015-07-02|2019-06-11|Tp Therapeutics, Inc.|Chiral diaryl macrocycles as modulators of protein kinases|

WO2017007759A1|2015-07-06|2017-01-12|Tp Therapeutics, Inc.|Diaryl macrocycle polymorph|

BR112017028604A2|2015-07-31|2018-09-04|Pfizer|lorlatinib free base crystalline form|

EP3355902A1|2015-09-30|2018-08-08|Merck Patent GmbH|Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer|

AU2016370846A1|2015-12-18|2018-07-05|Ignyta, Inc.|Combinations for the treatment of cancer|

EP3763693A1|2016-03-03|2021-01-13|Shenzhen TargetRx, Inc.|Macrocycle and composition comprising thereof|

CN105646355A|2016-04-07|2016-06-08|戊言医药科技（上海）有限公司|Preparation method of 3--1-methyl-pyrazole-5-formonitrile|

CN105732355A|2016-04-07|2016-07-06|戊言医药科技（上海）有限公司|Preparation method of 1-ethanone|

CA3019905A1|2016-04-08|2017-10-12|Pfizer Inc.|Crystalline forms of lorlatinib maleate|

US10301324B2|2016-04-12|2019-05-28|Atrin Pharmaceuticals LLC|Ataxia telengiectasia and rad3-relatedinhibitors and methods of their use|

CN105801603B|2016-04-13|2018-10-02|成都倍特药业有限公司|A kind of ALK inhibitor and preparation method thereof with macrocyclic structure|

WO2018137679A1|2017-01-25|2018-08-02|Teligene Ltd|Process for the Preparation of-7-amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile|

PE20200608A1|2017-06-30|2020-03-10|Bayer Animal Health Gmbh|NEW DERIVATIVES OF AZAQUINOLINE|

WO2019018570A1|2017-07-19|2019-01-24|Ignyta, Inc.|Pharmaceutical compositions comprising entrectinib|

RU2020113141A3|2017-10-10|2021-11-12|

WO2019077506A1|2017-10-17|2019-04-25|Ignyta, Inc.|Pharmaceutical compositions and dosage forms|

US11179412B2|2017-12-04|2021-11-23|University of Pittsburgh—of the Commonwealth System of Higher Education|Methods of treating conditions involving elevated inflammatory response|

WO2019126121A1|2017-12-19|2019-06-27|Tp Therapeutics, Inc.|Macrocyclic compounds for treating disease|

US20210163498A1|2018-04-23|2021-06-03|Pliva Hrvatska D.O.O.|Solid state forms of lorlatinib and their preparation|

WO2019210835A1|2018-05-04|2019-11-07|正大天晴药业集团股份有限公司|Diaryl macrocyclic compound as protein kinase modulator|

CN108621206B|2018-05-07|2020-08-14|昆山国显光电有限公司|Glove box system and maintenance method for glove box system|

EP3854397A1|2018-09-18|2021-07-28|Kabushiki Kaisha Yakult Honsha|Cancer combination therapy using quinoline carboxamide derivative|

CN109232607A|2018-09-20|2019-01-18|沈阳药科大学|Laura replaces the synthetic method of Buddhist nun|

CN109081810A|2018-09-20|2018-12-25|沈阳药科大学|The synthetic method of 1- methyl-3- methyl)-1H- pyrazoles-5- nitrile|

TW202038957A|2018-12-21|2020-11-01|日商第一三共股份有限公司|Combination of antibody-drug conjugate and kinase inhibitor|

CN109651398B|2019-01-25|2021-07-30|安庆多辉生物科技有限公司|Bromide intermediate for synthesizing Laratinib and method for catalytically synthesizing Laratinib|

CN109651418A|2019-01-25|2019-04-19|安庆多辉生物科技有限公司|A kind of method that Laura replaces Buddhist nun's bulk pharmaceutical chemicals synthetic intermediate and Organometallic Palladium catalytic coupling to prepare Laura for Buddhist nun|

CN109651397A|2019-01-25|2019-04-19|安庆多辉生物科技有限公司|A kind of Laura is for Buddhist nun's intermediate and prepares the method that Laura replaces Buddhist nun|

EP3941457A1|2019-03-21|2022-01-26|Merck Sharp & Dohme Corp.|Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection|

WO2020228747A1|2019-05-14|2020-11-19|Teligene Ltd|Substituted macrocycles useful as kinase inhibitors|

WO2021011345A1|2019-07-18|2021-01-21|Pliva Hrvatska D.O.O|Crystalline lorlatinib : fumaric acid and solid state form thereof|

CN110483551B|2019-08-30|2021-10-22|北京赛思源生物医药技术有限公司|Crystals of Laratinib free base|

WO2021069571A1|2019-10-10|2021-04-15|Sandoz Ag|Polymorph of lorlatinib|

CN111170908B|2020-01-09|2021-08-17|北京印刷学院|Synthesis method of 2, 4-dimethyl-3-methylsulfonyl halogeno-benzene|

WO2021176349A1|2020-03-05|2021-09-10|Pfizer Inc.|Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor|

WO2021226208A2|2020-05-05|2021-11-11|Nuvalent, Inc.|Heteroaromatic macrocyclic ether chemotherapeutic agents|

WO2022011123A1|2020-07-10|2022-01-13|Blossomhill Therapeutics, Inc.|Macrocycles and their use|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

US201261607485P| true| 2012-03-06|2012-03-06|

US201261607485P|2012-03-06|

US201361759307P| true| 2013-01-31|2013-01-31|

US201361759307P|2013-01-31|

PCT/IB2013/051391|WO2013132376A1|2012-03-06|2013-02-20|Macrocyclic derivatives for the treatment of proliferative diseases|

[返回顶部]